Xgene Pharmaceutical develops improved innovative drugs for major conditions including pain, seeking both clinical value and commercialization potential. Its lead oral nonopioid analgesic XG005 has secured a business development (BD) partnership. The company continues R&D and clinical translation of improved medicines to provide safer, more effective pain treatments
We have received your business plan. After completing an initial evaluation, our investment team will contact projects that align with our investment focus. Due to the volume of submissions, we appreciate your understanding if you do not receive a follow-up. We wish your project every success!
OK
This website uses cookies
This website uses cookies to improve your experience while you navigate through the website. You
can choose to opt-out if you wish. For more information, please refer to our
《Cookies》。